SOOLANTRA Drug Patent Profile
✉ Email this page to a colleague
When do Soolantra patents expire, and when can generic versions of Soolantra launch?
Soolantra is a drug marketed by Galderma Labs Lp and is included in one NDA. There are twelve patents protecting this drug and one Paragraph IV challenge.
This drug has seventy-seven patent family members in twenty-eight countries.
The generic ingredient in SOOLANTRA is ivermectin. There are five drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the ivermectin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Soolantra
A generic version of SOOLANTRA was approved as ivermectin by EDENBRIDGE PHARMS on October 24th, 2014.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for SOOLANTRA?
- What are the global sales for SOOLANTRA?
- What is Average Wholesale Price for SOOLANTRA?
Summary for SOOLANTRA
| International Patents: | 77 |
| US Patents: | 12 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 3 |
| Raw Ingredient (Bulk) Api Vendors: | 103 |
| Clinical Trials: | 6 |
| Drug Prices: | Drug price information for SOOLANTRA |
| Drug Sales Revenues: | Drug sales revenues for SOOLANTRA |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for SOOLANTRA |
| What excipients (inactive ingredients) are in SOOLANTRA? | SOOLANTRA excipients list |
| DailyMed Link: | SOOLANTRA at DailyMed |
Recent Clinical Trials for SOOLANTRA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Zydus Worldwide DMCC | Phase 3 |
| Catawba Research, LLC | Phase 3 |
Pharmacology for SOOLANTRA
| Drug Class | Antiparasitic Pediculicide |
Paragraph IV (Patent) Challenges for SOOLANTRA
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| SOOLANTRA | Cream | ivermectin | 1% | 206255 | 1 | 2016-12-30 |
US Patents and Regulatory Information for SOOLANTRA
SOOLANTRA is protected by twelve US patents.
Patents protecting SOOLANTRA
Treatment of papulopustular rosacea with ivermectin
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
Treatment of papulopustular rosacea with ivermectin
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
Treatment of inflammatory lesions of rosacea with ivermectin
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
Treatment of papulopustular rosacea with ivermectin
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
Treatment of papulopustular rosacea with ivermectin
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Galderma Labs Lp | SOOLANTRA | ivermectin | CREAM;TOPICAL | 206255-001 | Dec 19, 2014 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
| Galderma Labs Lp | SOOLANTRA | ivermectin | CREAM;TOPICAL | 206255-001 | Dec 19, 2014 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
| Galderma Labs Lp | SOOLANTRA | ivermectin | CREAM;TOPICAL | 206255-001 | Dec 19, 2014 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for SOOLANTRA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Galderma Labs Lp | SOOLANTRA | ivermectin | CREAM;TOPICAL | 206255-001 | Dec 19, 2014 | ⤷ Sign Up | ⤷ Sign Up |
| Galderma Labs Lp | SOOLANTRA | ivermectin | CREAM;TOPICAL | 206255-001 | Dec 19, 2014 | ⤷ Sign Up | ⤷ Sign Up |
| Galderma Labs Lp | SOOLANTRA | ivermectin | CREAM;TOPICAL | 206255-001 | Dec 19, 2014 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for SOOLANTRA
See the table below for patents covering SOOLANTRA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| South Korea | 20060004667 | TOPICAL FORMULATION OF IVERMECTIN FOR THE TREATMENT OF DERMATOLOGICAL CONDITIONS | ⤷ Sign Up |
| China | 105792829 | 使用伊维菌素治疗丘疹脓疱性红斑痤疮 (TREATMENT OF PAPULOPUSTULAR ROSACEA WITH IVERMECTIN) | ⤷ Sign Up |
| China | 111467301 | 使用伊维菌素治疗丘疹脓疱性红斑痤疮 (Treatment of papulopustular rosacea with ivermectin) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for SOOLANTRA
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1620113 | C01620113/01 | Switzerland | ⤷ Sign Up | PRODUCT NAME: IVERMECTINUM; REGISTRATION NO/DATE: AUTORISATION SWISSMEDIC 65561 20.12.2016 |
| 1620113 | 300756 | Netherlands | ⤷ Sign Up | PRODUCT NAME: IVERMECTINE VOOR TOEPASSING IN DE BEHANDELING VAN ROSACEA; NATIONAL REGISTRATION NO/DATE: RVG 115310 20150504; FIRST REGISTRATION: MT MA117/01101 20150402 |
| 1620113 | PA2015033,C1620113 | Lithuania | ⤷ Sign Up | PRODUCT NAME: IVERMEKTINAS; NAT. REGISTRATION NO/DATE: LT/1/15/3726/001 - LT/1/15/3726/005 20150513; FIRST REGISTRATION: MA117/01101 20150402 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
